Brokerages Expect Xylem Inc (XYL) Will Announce Quarterly Sales of $1.25 Billion

Equities analysts expect Xylem Inc (NYSE:XYL) to post $1.25 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Xylem’s earnings, with the highest sales estimate coming in at $1.29 billion and the lowest estimate coming in at $1.23 billion. Xylem reported sales of $1.22 billion during the same quarter last year, which indicates a positive year over year growth rate of 2.5%. The company is expected to issue its next earnings results before the market opens on Thursday, May 2nd.

According to Zacks, analysts expect that Xylem will report full year sales of $5.42 billion for the current financial year, with estimates ranging from $5.39 billion to $5.52 billion. For the next financial year, analysts anticipate that the firm will post sales of $5.70 billion, with estimates ranging from $5.66 billion to $5.75 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Xylem.

Xylem (NYSE:XYL) last released its earnings results on Thursday, January 31st. The industrial products company reported $0.88 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.88. The firm had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Xylem had a net margin of 10.54% and a return on equity of 19.89%.

Several equities analysts recently commented on XYL shares. Zacks Investment Research cut shares of Xylem from a “hold” rating to a “sell” rating in a research note on Saturday, January 12th. BMO Capital Markets reiterated a “buy” rating and set a $85.00 target price on shares of Xylem in a research note on Monday, February 25th. Boenning Scattergood reiterated a “buy” rating on shares of Xylem in a research note on Friday, March 22nd. ValuEngine cut shares of Xylem from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Stifel Nicolaus increased their price objective on shares of Xylem from $80.00 to $93.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $79.64.

NYSE:XYL traded up $0.16 during trading hours on Friday, hitting $82.93. 660,161 shares of the company traded hands, compared to its average volume of 872,537. The stock has a market cap of $14.92 billion, a P/E ratio of 28.80, a PEG ratio of 1.41 and a beta of 1.14. Xylem has a twelve month low of $60.65 and a twelve month high of $83.49. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.51 and a quick ratio of 1.08.

In other news, Director Steven R. Loranger sold 10,000 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $76.99, for a total value of $769,900.00. Following the completion of the transaction, the director now owns 26,744 shares in the company, valued at approximately $2,059,020.56. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Tomas Brannemo sold 559 shares of the stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $74.44, for a total transaction of $41,611.96. Following the sale, the insider now owns 10,568 shares of the company’s stock, valued at approximately $786,681.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 80,195 shares of company stock valued at $6,000,933. Corporate insiders own 0.85% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Halsey Associates Inc. CT acquired a new stake in shares of Xylem during the 4th quarter worth about $626,000. Pathlight Investors LLC acquired a new stake in shares of Xylem during the 4th quarter worth about $325,000. Rehmann Capital Advisory Group increased its position in shares of Xylem by 7,887.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 15,974 shares of the industrial products company’s stock worth $200,000 after purchasing an additional 15,774 shares in the last quarter. Hotaling Investment Management LLC acquired a new stake in shares of Xylem during the 4th quarter worth about $1,111,000. Finally, Mackay Shields LLC increased its position in shares of Xylem by 9.8% during the 4th quarter. Mackay Shields LLC now owns 31,442 shares of the industrial products company’s stock worth $2,097,000 after purchasing an additional 2,794 shares in the last quarter. Institutional investors and hedge funds own 86.64% of the company’s stock.

About Xylem

Xylem Inc engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation and treatment of water.

Further Reading: Depreciation

Get a free copy of the Zacks research report on Xylem (XYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xylem (NYSE:XYL)

Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.